Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719503 | 0.96 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL6395827 | 0.87 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10707551 | 0.86 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10706029 | 0.84 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3319199 | 0.84 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3322310 | 0.83 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10706375 | 0.82 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3537583 | 0.79 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3321177 | 0.78 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10707012 | 0.76 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877756-B2 | Substituted pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2032585-B1 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2029600-B1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | BOEHRINGER INGELHEIM INT (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-2029600-B1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | BOEHRINGER INGELHEIM INT (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | BOEHRINGER INGELHEIM INTERNATIONL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | BOEHRINGER INGELHEIM INTERNATIONL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | BOEHRINGER INGELHEIM INTERNATIONL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100120766-A1 | Substituted Pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-2032585-A2 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| EP-2029600-A1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | Boehringer Ingelheim International GmbH (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
| WO-2007135027-A1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135027-A1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135026-A2 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120766-A1 | Substituted Pteridines | PMP22, TLR5, NQO1 | PDE4A 1376/4885PDE4B 1580/4885PDE4C 1418/4885 |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | UACA, LTC4S, PMP22 | PDE4A 1509/4885PDE4B 1446/4885PDE4C 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.